



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 28, 2022

Gabrielle Heaton  
Director of Finance and Administration  
Kazia Therapeutics Ltd  
Three International Towers Level 24  
300 Barangaroo Avenue  
Sydney, New South Wales 2000  
Australia

**Re: Kazia Therapeutics Ltd**  
**Form 20-F for the fiscal year ended June 30, 2021**  
**Filed October 7, 2021**  
**File No. 000-29962**

Dear Ms. Heaton:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences